*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Evaluation of HER2-Neu status by immunohistochemistry and fluorescence in situ hybridization as a prognostic factor in gastric and gastro-esophageal cancer

Author: EAMAN SUUD KHALIFA, AYSER HAMEED LATIF
Abstract: Background: Amplification of the Intratumoral human epidermal growth factor receptor has been shown in a number of malignancies and few studies assess its role in gastric cancer. Objective: This study was conducted to evaluate the clinical utility of tissue Intratumoral human epidermal growth factor receptor in gastric cancer. Patients and methods : Clinical and pathological parameters were retrieved from medical folder in gastroenterology center/Baghdad medical city . Samples were classified according to Lauren’s Histopathological classification . Immunohistochemical staining of HER2 was manually performed using Anti ErbB2 mouse monoclonal (3b5). Out of the 74 specimens, three specimens expressing HER2-Neu was defined as IHC 2+ and subsequently was evaluated by fluorescence in situ hybridization. Results : An immunostaining was obvious in 19 sample (25.7%). Eleven patient, (14.9%) have complete membranous ring of immunostaining in 50% to 80% of the cells (a score IHC 3+) . Three patients, (4%) had a moderate stained membrane, covering 20%, 30% and 70% of the cells (a score IHC 2+) respectively. This finding was further evaluated with fluorescence in Situ Hybridization technique looking for gene overexpression. Five patients, (6.7% of cases) have faint staining with incomplete ring seen in 30% to 50% of the cells (a score IHC 1+) . Fifty five patient (74.3%) showed no immunostaining (an IHC score 0) . Conclusions: Perfect evaluation for HER2-Neu overexpression is essential to select patients for trastuzumab therapy.
Keyword: Gastric cancer , HER2-Neu Gene, Trastuzumab, Immunohistochemistry
DOI: https://doi.org/10.31838/ijpr/2021.13.01.354
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free